American Renal Associates Holdings, Inc (ARA): Price and Financial Metrics
ARA Price/Volume Stats
| Current price | $11.52 | 52-week high | $11.98 |
| Prev. close | $11.50 | 52-week low | $5.57 |
| Day low | $11.33 | Volume | 9,800 |
| Day high | $11.52 | Avg. volume | 106,940 |
| 50-day MA | $11.45 | Dividend yield | N/A |
| 200-day MA | $8.46 | Market Cap | 397.94M |
ARA Stock Price Chart Interactive Chart >
American Renal Associates Holdings, Inc (ARA) Company Bio
American Renal Associates provides outpatient dialysis services in the United States. The company focuses on joint venture relationships with nephrologists. It offers services to hospitals that include dialysis patient discharge coordination; and acute inpatient dialysis services, such as inpatient hemodialysis, inpatient peritoneal dialysis, C.V.V.H., C.R.R.T., and apheresis. The company was founded in 1999 and is based in Beverly, Massachusetts.
Latest ARA News From Around the Web
Below are the latest news stories about American Renal Associates Holdings Inc that investors may wish to consider to help them evaluate ARA as an investment opportunity.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – WTRE, ARA, RESI, NKNEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click here to learn more about your rights and options.American Renal Associates Holdings, Inc. (NYSE: ARA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Innovative Renal Care, LLC, an affiliate of Nautic Partners, LLC, for $11.50 per share in cash. If you are an American Renal shareholder, click here to learn more about your... |
Moore Kuehn Encourages CBMG, CLCT, TNAV, and ARA Investors to Contact Law FirmNEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: * Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) A proxy was recently filed with the SEC regarding the acquisition of Cellular Biomedicine by a consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned. The investigation concerns whether Cellular Biomedicine’s board of di... |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARAHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - STND, EIDX, WTRE, ARA, CGIXHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, EIDX, CIT, EMIS, FCNCA, FCNCB, EV, MS, NAV, STND, and WTREAmerican Renal Associates Holdings, Inc. (NYSE: ARA) |
ARA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 80.00% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 10.41% |
| 2019 | -9.98% |
Continue Researching ARA
Want to do more research on American Renal Associates Holdings Inc's stock and its price? Try the links below:American Renal Associates Holdings Inc (ARA) Stock Price | Nasdaq
American Renal Associates Holdings Inc (ARA) Stock Quote, History and News - Yahoo Finance
American Renal Associates Holdings Inc (ARA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...